Signos is a health technology company that provides a wearable continuous glucose monitoring (CGM) device combined with an AI-powered app for blood glucose pattern monitoring and personalized health recommendations. The platform recommends meals and exercises based on real-time glucose data detected through the connected device, helping users understand how different foods affect their glucose spike levels. The app provides personalized fitness and nutrition plans developed from continuous glucose monitoring data, enabling users to optimize their metabolic health, manage weight, and prevent metabolic diseases. Signos targets individuals seeking data-driven insights into their body's metabolic responses for proactive health management. Founded in 2020 and headquartered in San Francisco, United States, the company has raised $57 million in Series B funding from investors including Google Ventures, Dexcom Ventures, Samsung NEXT, and Courtside Ventures.
Signos
Series BSignos is a health technology company that provides a wearable continuous glucose monitoring (CGM) device combined with an AI-powered app for blood glucose pattern monitoring and personalized health recommendations. The platform recommends meals and exercises based on real-time glucose data detected through the connected device, helping users understand how different foods affect their glucose spike levels. The app…
About
Business model
Wearable Technology > Health and Wellness Devices > Diabetes Monitoring,
Disease Self Management > Diabetes > Monitoring > Glucose > Device > Wearable,
Diabetes > Medical Devices > Monitoring Devices > CGM > Non-Invasive
Founders & team highlights
Serial Founder
Team background
College Wise > Harvard University, Harvard Business School
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ Full list of active funds — filter by stage, check size, and geography.